-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Adenocarcinoma Of The Gastroesophageal Junction...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp Alfa in Gastric Cancer Drug Details: PRS-343 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bersiporocin in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bersiporocin in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bersiporocin in Idiopathic Pulmonary Fibrosis Drug Details: Bersiporocin (DWN-12088, DWJ-209) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Refractory Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Relapsed Acute Myeloid Leukemia Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cinrebafusp Alfa in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cinrebafusp...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ocifisertib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocifisertib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocifisertib in Triple-Negative Breast Cancer (TNBC) Drug Details: ocifisertib (CFI-400945)...
-
Product Insights
NewHernia Repair Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Hernia Repair Device is a hernia mesh used to cure hernia. Hernia is a condition where an organ or tissue bulges out through a weak spot in the surrounding muscle or connective tissue and can arise in a variety of locations throughout the body, including the pelvis, abdomen, and diaphragm. GlobalData's Medical Devices sector report, “Hernia Repair Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab Vedotin in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Lymphoma Drug Details: Zilovertamab vedotin is under development...